{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:25:38Z","timestamp":1790101538601,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T00:00:00Z","timestamp":1521763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Mov Disord"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40734-018-0069-3","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T01:22:44Z","timestamp":1522804964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Atrophy of the putamen at time of clinical motor onset in Huntington\u2019s disease: a 6-year follow-up study"],"prefix":"10.1186","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3273-3017","authenticated-orcid":false,"given":"Emma M.","family":"Coppen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"van der Grond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymund A. C.","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,23]]},"reference":[{"issue":"9","key":"69_CR1","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","volume":"8","author":"SJ Tabrizi","year":"2009","unstructured":"Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RAC, Durr A, Craufurd D, et al. Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9):791\u2013801.","journal-title":"Lancet Neurol"},{"issue":"6","key":"69_CR2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"JP Vonsattel","year":"1985","unstructured":"Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP. Neuropathological classification of Huntington\u2019s disease. J Neuropathol Exp Neurol. 1985;44(6):559\u201377.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"69_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"RAC Roos","year":"2010","unstructured":"Roos RAC. Huntington\u2019s disease: a clinical review. Orphanet J Rare Dis. 2010;5(1):40.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"69_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"The Huntington\u2019s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell. 1993;72(6):971\u201383.","journal-title":"Cell"},{"issue":"9","key":"69_CR5","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.biopsych.2011.07.030","volume":"71","author":"EH Aylward","year":"2012","unstructured":"Aylward EH, Liu D, Nopoulos PC, Ross CA, Pierson RK, Mills JA, et al. Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol Psychiatry. 2012;71(9):822\u20138.","journal-title":"Biol Psychiatry"},{"key":"69_CR6","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3174\/ajnr.A2018","volume":"31","author":"NZ Hobbs","year":"2010","unstructured":"Hobbs NZ, Barnes J, Frost C, Henley SMD, Wild EJ, Macdonald K, et al. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. Am J Neuroradiol. 2010;31:1036\u201341.","journal-title":"Am J Neuroradiol"},{"issue":"7","key":"69_CR7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","volume":"12","author":"SJ Tabrizi","year":"2013","unstructured":"Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RAC, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013;12(7):637\u201349.","journal-title":"Lancet Neurol"},{"issue":"11","key":"69_CR8","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s00415-008-0050-4","volume":"255","author":"CK Jurgens","year":"2008","unstructured":"Jurgens CK, Van De Wiel L, Van Es ACGM, Grimbergen YM, Witjes-An\u00e9 MNW, Van Der Grond J, et al. Basal ganglia volume and clinical correlates in \u201cpreclinical\u201d Huntington\u2019s disease. J Neurol. 2008;255(11):1785\u201391.","journal-title":"J Neurol"},{"issue":"3","key":"69_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00415-010-5768-0","volume":"258","author":"SJA van den Bogaard","year":"2011","unstructured":"van den Bogaard SJA, Dumas EM, Acharya TP, Johnson H, Langbehn DR, Scahill RI, et al. Early atrophy of pallidum and accumbens nucleus in Huntington\u2019s disease. J Neurol. 2011;258(3):412\u201320.","journal-title":"J Neurol"},{"issue":"5","key":"69_CR10","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1136\/jnnp.2004.047993","volume":"76","author":"CM Kipps","year":"2005","unstructured":"Kipps CM, Duggins AJ, Mahant N, Gomes L, Ashburner J, McCusker EA. Progression of structural neuropathology in preclinical Huntington\u2019s disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry. 2005;76(5):650\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"69_CR11","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/S1474-4422(14)70238-8","volume":"13","author":"JS Paulsen","year":"2014","unstructured":"Paulsen JS, Long JD, Ross CA, Harrington DL, Erwin CJ, Williams JK, et al. Prediction of manifest huntington\u2019s disease with clinical and imaging measures: a prospective observational study. Lancet Neurol. 2014;13(12):1193\u2013201.","journal-title":"Lancet Neurol"},{"issue":"5","key":"69_CR12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/ana.410410521","volume":"41","author":"J Penney","year":"1997","unstructured":"Penney J, Vonsattel JP, MacDonald M, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington\u2019s disease. Ann Neurol. 1997;41(5):689\u201392.","journal-title":"Ann Neurol"},{"issue":"4","key":"69_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","volume":"65","author":"DR Langbehn","year":"2004","unstructured":"Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length. Clin Genet. 2004;65(4):267\u201377.","journal-title":"Clin Genet"},{"issue":"2","key":"69_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group. Unified Huntington\u2019s disease rating scale: reliability and consistency. Mov Disord. 1996;11(2):136\u201342.","journal-title":"Mov Disord"},{"key":"69_CR15","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1016\/j.neuroimage.2004.07.051","volume":"23","author":"SM Smith","year":"2004","unstructured":"Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TEJ, Johansen-Berg H, et al. Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage. 2004 Jan;23:S208\u201319.","journal-title":"NeuroImage"},{"issue":"3","key":"69_CR16","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.neuroimage.2011.02.046","volume":"56","author":"B Patenaude","year":"2011","unstructured":"Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. NeuroImage. 2011;56(3):907\u201322.","journal-title":"NeuroImage"},{"issue":"3","key":"69_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/hbm.10062","volume":"17","author":"SM Smith","year":"2002","unstructured":"Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17(3):143\u201355.","journal-title":"Hum Brain Mapp"},{"issue":"2","key":"69_CR18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1006\/nimg.2002.1132","volume":"17","author":"M Jenkinson","year":"2002","unstructured":"Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. NeuroImage. 2002;17(2):825\u201341.","journal-title":"NeuroImage"},{"issue":"1","key":"69_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1006\/nimg.2002.1040","volume":"17","author":"SM Smith","year":"2002","unstructured":"Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage. 2002;17(1):479\u201389.","journal-title":"NeuroImage"},{"issue":"7","key":"69_CR20","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1136\/jnnp.2009.190702","volume":"81","author":"NZ Hobbs","year":"2010","unstructured":"Hobbs NZ, Henley SMD, Ridgway GR, Wild EJ, Barker RA, Scahill RI, et al. The progression of regional atrophy in premanifest and early Huntington\u2019s disease: a longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry. 2010;81(7):756\u201363.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"69_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/jnnp.2010.208264","volume":"82","author":"EH Aylward","year":"2011","unstructured":"Aylward EH, Nopoulos PC, Ross CA, Langbehn DR, Pierson RK, Mills JA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry. 2011;82(4):405\u201310.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"69_CR22","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1002\/mds.22601","volume":"24","author":"KM Biglan","year":"2009","unstructured":"Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, et al. Motor abnormalities in premanifest persons with Huntington\u2019s disease: the PREDICT-HD study. Mov Disord. 2009;24(12):1763\u201372.","journal-title":"Mov Disord"},{"key":"69_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.parkreldis.2017.11.001","volume":"46","author":"EM Coppen","year":"2018","unstructured":"Coppen EM, Jacobs M, van den Berg-huysmans AA, van der Grond J, Roos RAC. Grey matter volume loss is associated with specific clinical motor signs in Huntington\u2019s disease. Park Relat Disord. 2018;46:56\u201361.","journal-title":"Park Relat Disord"},{"issue":"1","key":"69_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","volume":"11","author":"SJ Tabrizi","year":"2012","unstructured":"Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, et al. Potential endpoints for clinical trials in premanifest and early Huntington\u2019s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 2012;11(1):42\u201353.","journal-title":"Lancet Neurol"},{"issue":"4","key":"69_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/jnnp.2009.176982","volume":"81","author":"J Rupp","year":"2010","unstructured":"Rupp J, Blekher T, Jackson J, Beristain X, Marshall J, Hui S, et al. Progression in prediagnostic Huntington disease. J Neurol Neurosurg Psychiatry. 2010;81(4):379\u201384.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Clinical Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40734-018-0069-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40734-018-0069-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40734-018-0069-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T20:20:54Z","timestamp":1553286054000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalmovementdisorders.biomedcentral.com\/articles\/10.1186\/s40734-018-0069-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,23]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["69"],"URL":"https:\/\/doi.org\/10.1186\/s40734-018-0069-3","relation":{},"ISSN":["2054-7072"],"issn-type":[{"value":"2054-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,23]]},"assertion":[{"value":"20 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The local Medical Ethical Committee approved this study and written informed consent was obtained from all participants included in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Emma M. Coppen and Jeroen van der Grond report no competing interest. Raymund A.C. Roos receives grants from TEVA Pharmaceuticals, Cure Huntington\u2019s Disease Initiative (CHDI), Gossweiler Foundation, and is member of the advisory board of UniQure.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"2"}}